Back to News
Market Impact: 0.42

Lululemon stock price target cut to $115 by Freedom Broker on weak quarter

Source: Investing.com

Monetary PolicyInterest Rates & YieldsCorporate EarningsCorporate Guidance & OutlookAnalyst InsightsConsumer Demand & Retail
Lululemon stock price target cut to $115 by Freedom Broker on weak quarter

Lululemon shares trade around $101.09 after falling 41% year-to-date, following Q2 revenue down 4.3% YoY to $2.42B and global comparable sales down 9% (10% constant-currency). The company cut Q3 revenue guidance to $2.29B–$2.32B (down 10%–11% YoY) and reduced FY2026 revenue guidance to $10.35B–$10.50B (down 5%–7%) while lowering diluted EPS guidance to $9.48–$9.73. Multiple analysts trimmed price targets (e.g., Freedom Broker to $115 from $139, Stifel to $100, Morgan Stanley to $83), reflecting a weak demand outlook alongside broader market risk as a blockbuster jobs report boosts Fed rate-hike bets.

Analysis

This is a classic case of earnings deterioration outrunning multiple compression. The stock can look optically cheap on trailing earnings, but the real question is whether the brand still deserves a premium once comp momentum is gone; if not, the market will keep re-rating it toward a lower-growth apparel name rather than a franchise retailer. The immediate mechanism is simple: weaker traffic plus lower sell-through means less pricing power, and that hits not just revenue but the quality of future earnings estimates.

The bigger second-order risk is competitive leakage. In premium athletic wear, a softening LULU usually implies either share shift to scale players with broader innovation budgets (NKE) or trade-down into value athletic brands and private label; if management defends share with promotions, gross margin can roll fast from here despite the current cushion. On the supply chain side, lower order volumes can pressure vendors and freight commitments with a lag, so the damage often shows up first in guidance revisions before it becomes visible in reported margins.

Catalyst-wise, the next 1-3 months matter more than the next quarter: analyst cuts, holiday booking checks, and any inventory/markdown commentary will determine whether this is a one-off reset or the start of a multi-quarter de-rating. Over 6-18 months, the new CEO and international store rollout can stabilize growth, but that is too slow to offset a U.S. demand slowdown if real rates stay restrictive. The contrarian miss is that consensus is treating this as a valuation story; it is really a demand and mix story, and the thesis is only falsified if North America comps reaccelerate, operating margin holds above the current guide, or management proves the launch pipeline can restore traffic without discounting.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

moderately negative

Sentiment Score

-0.45

Ticker Sentiment

LULU-0.85

Key Decisions for Investors

  • Short LULU on any post-downgrade bounce; use a 1-3 month put spread (e.g., 95/85) to express downside to the low-90s while defining risk. Falsify if U.S. comps inflect positive or Q3 revenue comes in near the high end of guidance.
  • Pair trade: long NKE / short LULU for 1-3 months. The thesis is that broad-scale brand and distribution advantages should absorb share better than a single-category premium name under pressure. Risk: if consumer demand improves sharply, the short leg may underperform while the long leg lags less.
  • If you want cleaner delta exposure, wait for a relief rally and then add to short LULU rather than chasing weakness. The best entry is after a gap-up on analyst activity, not into a flush where borrow/vol can get expensive.
  • Set a watch on TGT as a trade-down beneficiary, but do not initiate blind. If upcoming retail data show consumers shifting lower on the basket, TGT can outperform relative to premium discretionary; if not, the read-through is just broader softness, not share capture.

More News

From AllMind Research

Browse all research